#TradFi交易分享挑战

Decoding Moderna's Stock Price—Can It Make a Comeback After a 95% Plunge?

2025: Deep Adjustment and Survival Pressure

Affected by a sharp decline in COVID-19 vaccine demand, Moderna's stock price fell to a historic low of $22.28 in November 2025, down over 95% from its peak of $484.47 in 2021, with market capitalization shrinking to less than $9 billion. Full-year revenue declined to $1.9 billion, net losses narrowed to $280 million, but cash flow remained under pressure, forcing layoffs of 10%, cutting several non-core pipelines, and borrowing $1.5 billion from Ares Management to sustain operations.

2026: Initial Results of Strategic Transformation, Stock Price Stabilizes in the $47–$50 Range

In early 2026, with the retail penetration of mNEXSPIKE (next-generation COVID-19 vaccine) reaching 34% among Americans aged 65 and above, and approvals in Canada and Australia, the company's revenue structure gradually optimized. After the February 2026 earnings report, the stock rose 8.48% in a single day, reflecting market recognition of cost-cutting effects and commercialization pathways for non-COVID products. As of May 29, 2026, the stock stabilized at $47.19, with a 52-week range of $22.28–$50.15. Technical analysis shows "bottoming oscillations with moderate volume expansion," indicating weakening bearish pressure and beginning of tentative bullish positioning.

Core Driving Logic: From "Vaccine Company" to "Platform Biotech Enterprise"

Currently, the stock price no longer relies on a single product but is anchored on three major structural changes:

① Cost Structure Optimization: R&D and sales expenses reduced by over 30% year-over-year in 2025;

② Product Pipeline Focus: Fully advancing clinical translation of flu vaccines, personalized cancer vaccines (such as mRNA-4157/V940), and RSV vaccine mRESVIA;

③ Geopolitical and Policy Benefits: U.S. "Reshoring Biomanufacturing" policy promotes domestic capacity expansion, supported by federal funding, enhancing long-term certainty.

Current Market Perception: Valuation Still Has Repair Potential

Although the company remains unprofitable (TTM P/E ratio negative), its trend of free cash flow improvement, mRNA platform reusability, and global public health collaboration network are being reevaluated by institutional investors. The average analyst target price is $48.99, with the current stock price close to the midpoint. Future upside momentum will depend on clinical data readouts for tumor vaccines in 2026–2027 and commercial volume growth of flu vaccines.

Risk Warning

If Phase III trials of mRNA-4157 in adjuvant melanoma treatment fail to meet primary endpoints, or if the flu vaccine does not receive approval before fall 2026, the stock price could face renewed pressure. The current trend is a "weak recovery," not yet entering a "high-growth" phase. $MRNA